Press release from Companies
Publicerat: 2023-02-24 08:00:00
Today, 24 February 2023, is the first day of the subscription period in Polymer Factory Sweden AB’s ("Polymer Factory" or the "Company") rights issue of shares with pre-emptive rights for existing shareholders (the "Rights Issue"). The public is also given the opportunity to subscribe for shares in the Rights Issue. The subscription period runs until, and including, 10 March 2023. The Rights Issue can, if fully subscribed, provide the Company with a maximum amount of approx. SEK 8.8 million before deduction of transaction related costs. Approx. 70 percent of the Rights Issue is secured in writing through pre-subscription and underwriting commitments. The memorandum and teaser are available on Polymer Factory’s (www.polymerfactory.com), Sedermera Corporate Finance AB’s (www.sedermera.se), Nordic Issuing AB’s (www.nordic-issuing.se) and Spotlight Stock Market’s (www.spotlightstockmarket.com) respective websites.
Background Since its listing on Spotlight Stock Market in 2021, Polymer Factory has focused on the process of strengthening the organization as well as increasing sales. The Company not only closed the year 2021 with increased revenues but also launched a new product segment, BowtieD®. During the first half of 2022, Polymer Factory primarily focused on expanding the team and deepening relationships with customers, while continuing to engage new leads. On the product development side, Polymer Factory progressed with the product launch of Dendritic Nanogel (DNG) in Q4 2022 as a future competitor to liposome carriers and organic/inorganic nanoparticle carriers as well as the expansion of the SpheriCal® calibrant platform. During Q4 2022, the net sales in Polymer Factory rose to approx. SEK 1 million, compared to the same period the previous year when turnover was approx. SEK 759,000. In December 2022, Polymer Factory received certification for its quality management system (ISO 13485) – an internationally recognized standard designed to be used by organizations involved in design and manufacturing of medical devices and related services. The ISO-certification underlines the quality in the Company’s work in developing products. Motive To finance future objectives and growth, Polymer Factory has decided to conduct a Rights Issue of shares. The Offer can provide the Company with a total of approx. SEK 8.8 million, before the deduction of transaction related costs. The proceeds are intended to finance a continued acceleration of sales by, among other things, increased sales and marketing activities, employment of an additional sales resource, expansion of the organization by adding resources to meet increased demand and continue to build and maintenance the Company’s portfolio of IP rights and ISOs. The offer in brief Important dates For more information about the Rights Issue, please contact: For more information about Polymer Factory, please contact: Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.
Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com